Folks at Johnson & Johnson (NYSE:JNJ) have a reason to celebrate as the Federal Drug Agency recently approved its schizophrenia treatment.
After successful drug trials involving a lot of hours from the research and development team at Johnson and Johnson, the efforts have paid off. The FDA approved the schizophrenia drug after careful review, giving the pharmaceutical company the go-ahead sign for the next stage.
According to the drug manufacturer, the new drug called Invega Trinza has the longest duration in between dosages. This aspect of the drug makes it a preferable option for schizophrenia. The longevity makes it a cheaper option while at the same time giving the patients an opportunity to not have to worry about regular drug follow up.
The drug was developed at Janssen Pharmaceuticals Inc., which is a tributary of the parent company, Johnson & Johnson (NYSE:JNJ). Invega Trinza was presented for review in January. The pharmaceutical company announced that the drug will only be administered once the patients have first been treated with a drug called Invega Sustenna. The drug must be administered in form of an injection once every month for four months. After that the new drug can then be administered.
Invega Trinza will be administered once every three months in the form of an injection making it a one-time injection treatment per year. The drug is good news for schizophrenia patients as it can get rid of short term symptoms and place focus on the long-term recovery process.
The drug trials for the new treatment revealed that 93% of the test subjects reported that they did not experience any significant schizophrenia symptoms. These research findings were published in March. The drug’s successful trials and positive response contributed to the FDA’s decision to approve it. The agency even cut down the review process down to 6 months from the regular ten months.
Schizophrenia affects more than 21 million individuals worldwide. The new drug will change the lives of most of these people once they can access it.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: